Ejaculatory disorders after prostatic artery embolization: a reassessment of two prospective clinical trials

Springer Science and Business Media LLC - Tập 38 - Trang 2595-2599 - 2019
Gautier Müllhaupt1, Lukas Hechelhammer2, Pierre-André Diener3, Daniel S. Engeler1, Sabine Güsewell4, Hans-Peter Schmid1, Livio Mordasini1, Dominik Abt1
1Department of Urology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland
2Department of Radiology and Nuclear Medicine, St. Gallen Cantonal Hospital, St. Gallen, Switzerland
3Department of Pathology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland
4Clinical Trials Unit, St. Gallen Cantonal Hospital, St. Gallen, Switzerland

Tóm tắt

This study aims to specify and explain the previous findings of unexpectedly high rates of ejaculatory disorders, i.e. 56%, found after prostatic artery embolization (PAE) in a randomized controlled trial comparing safety and efficacy of PAE and transurethral resection of the prostate (TURP). Case report forms of the randomized controlled trial were analyzed to specify the grade of postoperative ejaculatory dysfunction 3 months postoperatively. In addition, study participants with assessable ejaculation were asked to complete the four-item Male Sexual Health Questionnaire-Ejaculation Dysfunction Short Form (MSHQ-EjD) referring to their ejaculatory function at present, as well as before treatment and 3 months after. Potential explanations for ejaculatory disorders after PAE were derived from histological examination of five radical prostatectomy specimens of patients that underwent PAE 6 weeks before radical prostatectomy within a proof-of-concept trial at the study site, St. Gallen Cantonal Hospital. An experienced uropathologist systematically examined the whole-gland embedded tissue with focus on structures that are involved into ejaculation. While patients after TURP predominantly suffered from anejaculation (52%), diminished ejaculation was found more often after PAE (40%). Significantly higher MSHQ-EjD scores were found 3 months after PAE and at a median follow-up of 31 months. Histological examination showed marked changes of structures involved into ejaculation (e.g., prostatic glands, seminal vesicles, ejaculatory ducts) after PAE. Although anejaculation occurs less frequently after PAE (16%) compared to TURP (52%), patients have to be informed about the relevant risk of ejaculatory disorders, especially diminished ejaculation.

Tài liệu tham khảo

Lebdai S, Chevrot A, Doizi S, Pradere B, Delongchamps NB, Benchikh A, Cornu JN, Della Negra E, Fourmarier M, Misrai V, Theveniaud PE, Descazeaud A, Robert G, CTMH-AFU Group (2019) Do patients have to choose between ejaculation and miction? A systematic review about ejaculation preservation technics for benign prostatic obstruction surgical treatment. World J Urol. 37(2):299–308. https://doi.org/10.1007/s00345-018-2368-6(epub 2018 Jul 2) Shim SR, Kanhai KJ, Ko YM, Kim JH (2017) Efficacy and safety of prostatic arterial embolization: systematic review with meta-analysis and meta-regression. J Urol 197(2):465–479. https://doi.org/10.1016/j.juro.2016.08.100 Ray AF, Powell J, Speakman MJ, Longford NT, DasGupta R, Bryant T, Modi S, Dyer J, Harris M, Carolan-Rees G, Hacking N (2018) Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). BJU Int 122(2):270–282. https://doi.org/10.1111/bju.14249 Abt D, Hechelhammer L, Mullhaupt G, Markart S, Gusewell S, Kessler TM, Schmid HP, Engeler DS, Mordasini L (2018) Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ 361:k2338. https://doi.org/10.1136/bmj.k2338 National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) version 4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf Mordasini L, Hechelhammer L, Diener PA, Diebold J, Mattei A, Engeler D, Mullhaupt G, Kim SK, Schmid HP, Abt D (2018) Prostatic artery embolization in the treatment of localized prostate cancer: a bicentric prospective proof-of-concept study of 12 patients. J Vasc Interv Radiol 29(5):589–597. https://doi.org/10.1016/j.jvir.2018.01.766 Rosen RC, Catania JA, Althof SE, Pollack LM, O'Leary M, Seftel AD, Coon DW (2007) Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction. Urology 69(5):805–809. https://doi.org/10.1016/j.urology.2007.02.036 Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151(1):54–61 Kim JK, Cho MC, Son H, Ku JH, Oh SJ, Paick JS (2017) Patient perception of ejaculatory volume reduction after holmium laser enucleation of the prostate (HoLEP). Urology 99:142–147. https://doi.org/10.1016/j.urology.2016.09.037